Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial

Abstract Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. Methods We conducted a first‐in‐human phase I study using TLR7/8‐matured DCs transfected with RNA encoding the two AML...

Full description

Bibliographic Details
Main Authors: Felix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, Katrin Deiser, Torben Altmann, Veit L Bücklein, Thomas Köhnke, Christian Augsberger, Nikola P Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Boehm, Melanie Boxberg, Mirjam HM Heemskerk, Dennis Goerlich, Georg Wittmann, Beate Wagner, Wolfgang Hiddemann, Dolores J Schendel, Gunnar Kvalheim, Iris Bigalke, Marion Subklewe
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical & Translational Immunology
Subjects:
acute myeloid leukaemia
cancer vaccines
clinical trials
dendritic cell vaccination
immunotherapy
Online Access:https://doi.org/10.1002/cti2.1117

Internet

https://doi.org/10.1002/cti2.1117

Similar Items